Cargando…
鉴定晚期肺腺癌EGFR-T790M耐药基因突变候选生物标志物
BACKGROUND AND OBJECTIVE: Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. Osimertinib therapy was missed in many patients who were unable to perform biopsy due to occult lesion progression or weak body. In t...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679218/ https://www.ncbi.nlm.nih.gov/pubmed/33203197 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.20 |